Related Experiment Video
Updated: May 2, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
MicroRNAs and dendritic cell-based vaccination in melanoma patients
Francesco de Rosa1, Francesca Fanini, Massimo Guidoboni
1aImmunotherapy Unit bGene Therapy Unit cDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy dDepartment of Pediatrics and Molecular Microbiology & Immunology, Norris Comprehensive Cancer Center, the Saban Research Institute and Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Abstract:
MicroRNAs are increasingly being recognized to play an important role in finely tuning gene expression; therefore, their dysregulation in cancer has been investigated extensively. In terms of melanoma, they are involved in the regulation of many genes and pathways impacting invasiveness, dissemination, and disease progression. Many microRNAs also target genes regulating ontogenesis and functions of the immune system. Indeed, fine-tuning of gene expression by microRNAs is necessary for normal differentiation of the various components of the immune system and for mounting an effective innate and cell-mediated response, which has been shown to be able to control tumor growth. Dendritic cells, by presenting antigens to and activating naive T cells, constitute a critical aspect and have been therefore been used in many studies of cancer vaccination with promising results. Many genes regulating functions and plasticity of dendritic cells are indeed targeted by microRNAs, whose expression is also dependent on maturation status. Therefore, microRNAs could provide new potential therapeutic targets both on the tumor and on the immune system, and could also be used to characterize dendritic cells utilized in immunotherapy trials.
Insights
MicroRNAs regulate gene expression and are crucial for immune cell function. Their dysregulation in melanoma impacts disease progression and immune response, offering potential therapeutic targets.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- MicroRNAs (miRNAs) are key regulators of gene expression.
- Dysregulated miRNAs are implicated in various cancers, including melanoma.
- miRNAs influence immune system ontogenesis and function, impacting anti-tumor responses.
Purpose of the Study:
- To investigate the role of microRNAs in melanoma progression and immune regulation.
- To explore microRNAs as potential therapeutic targets in cancer immunotherapy.
- To assess microRNAs for characterizing dendritic cells in immunotherapy.
Main Methods:
- Literature review on microRNA function in melanoma and immunology.
- Analysis of microRNA targeting of genes involved in immune cell function.
- Exploration of microRNA's role in dendritic cell biology and maturation.
Main Results:
- MicroRNAs significantly impact melanoma invasiveness, dissemination, and progression.
- MicroRNAs are essential for immune cell differentiation and anti-tumor responses.
- Dendritic cell functions and plasticity are regulated by microRNAs.
Conclusions:
- MicroRNAs represent promising therapeutic targets for both melanoma and immune system modulation.
- MicroRNAs can serve as biomarkers for dendritic cell characterization in immunotherapy trials.
- Targeting microRNAs may enhance cancer immunotherapy efficacy.
